SHAREHOLDER INVESTIGATION: Faruqi & Faruqi, LLP Examining Potential Securities Law Violations at Telix Pharmaceuticals

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Telix To Contact Him Directly To Discuss Their Options

If you suffered losses in Telix and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

[You may also click here for additional information]

NEW YORK–(BUSINESS WIRE)–$TLX #ClassAction—Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Telix Pharmaceuticals Limited (“Telix” or the “Company”) (NASDAQ: TLX).

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

On July 22, 2025, Telix Pharmaceuticals revealed that it “received a subpoena from the U.S. Securities and Exchange Commission . . . seeking various documents and information primarily relating to the Company’s disclosures regarding the development of the Company’s prostate cancer therapeutics candidates.”

On this news, the price of Telix Pharmaceuticals American Depositary Shares (“ADSs”) fell more than 13% over two trading sessions, according to the complaint.

Then, on August 28, 2025, the complaint further alleges that Telix Pharmaceuticals disclosed that it received a Complete Response Letter from the U.S. Food and Drug Administration (“FDA”) for the Biologics License Application for its product TLX250-CDx, which identified “deficiencies relating to the Chemistry, Manufacturing, and Controls (CMC) package.” The FDA additionally “documented notices of deficiency (Form 483) issued to two third-party manufacturing and supply chain partners that will require remediation prior to resubmission.”

The Telix Pharmaceuticals class action lawsuit alleges that on this news, the price of Telix Pharmaceuticals ADSs fell more than 21% over two trading sessions.

To learn more about the Telix Pharmaceuticals investigation, go to www.faruqilaw.com/TLX or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Follow us for updates on LinkedIn, on X, or on Facebook.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

Contacts

Josh Wilson

877-247-4292 or 212-983-9330 (Ext. 1310)